MX9201805A - Derivados de n-imidazolilo de indol substituido, procedimiento para su preparacion y composicion farmaceutica que los contiene. - Google Patents

Derivados de n-imidazolilo de indol substituido, procedimiento para su preparacion y composicion farmaceutica que los contiene.

Info

Publication number
MX9201805A
MX9201805A MX9201805A MX9201805A MX9201805A MX 9201805 A MX9201805 A MX 9201805A MX 9201805 A MX9201805 A MX 9201805A MX 9201805 A MX9201805 A MX 9201805A MX 9201805 A MX9201805 A MX 9201805A
Authority
MX
Mexico
Prior art keywords
branched
alkyl
straight
imidazolyl
derivatives
Prior art date
Application number
MX9201805A
Other languages
English (en)
Inventor
Patricia Salvati
Angelo Daniele Volpi
Paolo Cozzi
Antonio Pillan
Maurizio Pulici
Original Assignee
Erba Carlo Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Erba Carlo Spa filed Critical Erba Carlo Spa
Publication of MX9201805A publication Critical patent/MX9201805A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a derivados de N-imidazolilo de indol sustituido, de fórmula general (I) en donde p es un número entero de 1 a 4; A es una cadena de alquileno de 1 a 4 átomos de carbono recta o ramificada; B es un enlace directo, una cadena de hidrocarburo de 1 a 4 átomos de carbono recta o ramificada, insaturado o saturado; Q es una cadena de hidrocarburo de 1 a 9 átomos de carbono recta o ramificada, saturado o insaturado, o la cadena está interrumpida por un átomo de oxígeno; cada uno de R1 y R2 independientemente es hidrógeno, alquilo de 1 a 4 átomos de carbono, alcoxi de 1 a 4 átomos de carbono, alquiltio de 1 a 4 átomos de carbono, alquilsulfonilo de 1 a 4 átomos de carbono, halógeno o trihalometilo; cada uno de R3 y R5, independientemente es hidrógeno o alquilo de 1 a 4 átomos de carbono; R4 es un grupo -OR6 o -N(R6R7), en donde cada uno de R6 y R7 independientemente es hidrógeno, alquilo de 1 a 4 átomos de carbono, fenilo o bencilo; o una sal farmacéuticamente aceptable de los mismos, que son útiles en el tratamiento de un estado de enfermedad, en el cual un aumento de la síntesis del TxA2 ejerce un efecto patogénico.
MX9201805A 1991-04-24 1992-04-20 Derivados de n-imidazolilo de indol substituido, procedimiento para su preparacion y composicion farmaceutica que los contiene. MX9201805A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919108811A GB9108811D0 (en) 1991-04-24 1991-04-24 N-imidazolyl derivatives of substituted indole

Publications (1)

Publication Number Publication Date
MX9201805A true MX9201805A (es) 1994-07-29

Family

ID=10693860

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9201805A MX9201805A (es) 1991-04-24 1992-04-20 Derivados de n-imidazolilo de indol substituido, procedimiento para su preparacion y composicion farmaceutica que los contiene.

Country Status (16)

Country Link
US (1) US5246957A (es)
EP (1) EP0510398A3 (es)
JP (1) JPH05132482A (es)
KR (1) KR920019779A (es)
AU (1) AU647907B2 (es)
CA (1) CA2066938A1 (es)
FI (1) FI921794A (es)
GB (1) GB9108811D0 (es)
HU (1) HUT60730A (es)
IE (1) IE921314A1 (es)
IL (1) IL101453A (es)
MX (1) MX9201805A (es)
MY (1) MY131096A (es)
NZ (1) NZ242377A (es)
RU (1) RU2073669C1 (es)
TW (1) TW213911B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5451597A (en) * 1993-05-27 1995-09-19 G.D. Searle & Co. Treatment of circulatory disorders using n-substituted (α-imidazolyl-toluyl) pyrrole angiotensin II antagonists
AU685122B2 (en) * 1993-06-14 1998-01-15 Pfizer Inc. Imidazole lipoxygenase inhibitors
JPH0867866A (ja) 1994-06-20 1996-03-12 Canon Inc 光重合剤及び／又は光架橋剤に対する可視光増感剤、感光性組成物及びホログラム記録媒体
TW397821B (en) * 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US5880137A (en) * 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
DE69830069T3 (de) * 1997-10-17 2012-02-09 Ark Therapeutics Ltd. Verwendung von hemmern des renin-angiotensin systems zur behandlung von hypoxie oder verringertem stoffwechsel
US6069153A (en) * 1998-05-12 2000-05-30 American Home Products Corporation Indenoindoles and benzocarbazoles as estrogenic agents
US6479535B1 (en) 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
US6159959A (en) * 1999-05-06 2000-12-12 American Home Products Corporation Combined estrogen and antiestrogen therapy
CA2565628A1 (en) * 2004-05-03 2005-11-10 Astellas Pharma Inc. The combination of prostaglandin e2 receptor antagonist and renin-angiotensin system inhibitor for treating renal diseases
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
TW200920369A (en) 2007-10-26 2009-05-16 Amira Pharmaceuticals Inc 5-lipoxygenase activating protein (flap) inhibitor
MX2010012814A (es) 2008-05-23 2010-12-20 Amira Pharmaceuticals Inc Inhibidor de proteina activadora de 5-lipoxigenasa.
US8546431B2 (en) 2008-10-01 2013-10-01 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH455777A (de) * 1965-05-13 1968-05-15 Geigy Ag J R Verfahren zur Herstellung von neuen Indolderivaten
GR75101B (es) * 1980-10-23 1984-07-13 Pfizer
ZA825413B (en) * 1981-08-26 1983-06-29 Pfizer Thromboxane synthetase inhibitors, processes for their production, and pharmaceutical compositions comprising them
CA1241660A (en) * 1984-06-25 1988-09-06 Yvan Guindon Indole-2-alkanoic acids
JPS63501215A (ja) * 1985-10-30 1988-05-12 ジ・アップジョン・カンパニー ３’−ピリジニルアルキルインデン−および３’−ピリジニルアルキルインドール−２−カルボン酸および同族体
NZ222878A (en) * 1986-12-17 1991-02-26 Merck Frosst Canada Inc 3-hetero-substituted-n-benzyl-indole derivatives, and pharmaceutical compositions
US5081138A (en) * 1986-12-17 1992-01-14 Merck Frosst Canada, Inc. 3-hetero-substituted-n-benzyl-indoles and prevention of leucotriene synthesis therewith
GB8814277D0 (en) * 1988-06-16 1988-07-20 Glaxo Group Ltd Chemical compounds
IL91542A0 (en) * 1988-10-06 1990-04-29 Erba Carlo Spa N-imidazolyl-and n-imidazolyl-methyl derivatives of substituted bicyclic compounds,their preparation and pharmaceutical compositions containing them
IT1227362B (it) * 1988-11-18 1991-04-08 Istituto Biochimico Italiano Derivati indolici, processo per la loro preparazione e loro uso comefarmaci antitrombotici
DE4010797A1 (de) * 1990-04-04 1991-10-10 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung

Also Published As

Publication number Publication date
HU9201246D0 (en) 1992-07-28
EP0510398A3 (en) 1993-01-13
IE921314A1 (en) 1992-11-04
RU2073669C1 (ru) 1997-02-20
KR920019779A (ko) 1992-11-20
FI921794A0 (fi) 1992-04-22
FI921794A (fi) 1992-10-25
EP0510398A2 (en) 1992-10-28
AU1407992A (en) 1992-10-29
CA2066938A1 (en) 1992-10-25
US5246957A (en) 1993-09-21
AU647907B2 (en) 1994-03-31
GB9108811D0 (en) 1991-06-12
JPH05132482A (ja) 1993-05-28
TW213911B (es) 1993-10-01
IL101453A0 (en) 1992-12-30
NZ242377A (en) 1993-09-27
HUT60730A (en) 1992-10-28
IL101453A (en) 1996-05-14
MY131096A (en) 2007-07-31

Similar Documents

Publication Publication Date Title
MX9201805A (es) Derivados de n-imidazolilo de indol substituido, procedimiento para su preparacion y composicion farmaceutica que los contiene.
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
EA200500174A1 (ru) Новые производные бензимидазола, полезные в качестве антипролиферативных агентов
UY28132A1 (es) Derivados de pirrolopirimidina
CO5550421A2 (es) Derivados de indol utiles para el tratamiento de enfermeda- des
MX2007004183A (es) Derivados de benzoimidazol utiles como agentes antiproliferacion.
CY1106674T1 (el) Αζαδικυκλικοι ετεροκυκλοι σαν ρυθμιστες υποδοχεα κανναβινοειδους
EA200401056A1 (ru) Комбинация, содержащая производные тропана, полезные в терапии
PA8546601A1 (es) Nuevos derivados de indol con afinidad por el receptor 5-ht6
CR20140368A (es) Derivados y composiciones de isoindol 4´-0-sustituidos, composiciones que las comprenden y metodos de uso de los mismos (divisional 11036)
FR2714378B1 (fr) Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant.
PA8556801A1 (es) Compuestos de imidazopiridin como moduladores de receptor 5-ht 4
AR028810A1 (es) Derivados de arilpiperazinil-ciclohexil indol, composiciones farmaceuticas que los comprenden y el uso de los mismos para la manufactura de medicamentos para el tratamiento de la depresion
NO20023997L (no) 2-okso-1-pyrrolidinderivater, fremgangsmåter for deres fremstilling, og deres anvendelse
EA199900937A1 (ru) Фармацевтические композиции, содержащие вориконазол
NO20025641D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
RU94044671A (ru) Применение непептидных антагонистов рецептора тахикинина
PT1263730E (pt) Derivados amina para o tratamento de apoptose
CO5611152A2 (es) Compuestos derivados piperidina caracterizados por ser antagonistas del receptor de las taquicininas, especialmente del receptor nk1 y composiciones farmaceuticas que los contienen
NO20025640D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
AP2002002664A0 (en) Cyclohexylamine derivative as subtype selective NMDA receptor antagonists.
MX9306311A (es) Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
AR007997A1 (es) Un derivado de distamicina sustituida con acriloilo, sus utilizaciones, un procedimiento para producirlo y una composicion farmaceutica que lo comprende.
ES2189173T3 (es) Derivados de 20-aril-5alfa-pregnano.
MX9200178A (es) DERIVADOS DE N-IMIDAZOLILO DE CICLOHEPT (b) INDOL Y TETRAHIDROCARBAZOL SUBSTITUIDOS Y COMPOSICION FARMACEUTICA QUE LOS CONTIENE.